Recursion Pharmaceuticals (RXRX) Non-Current Debt (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Non-Current Debt came in at $7.2 million in Q1 2026, down 56.34% YoY from $16.4 million in Q1 2025, and down 24.92% on a QoQ basis from $9.6 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Non-Current Debt (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Non-Current Debt data on file, last reported at $7.2 million in Q1 2026.
- Quarterly Non-Current Debt fell 56.34% year-over-year to $7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (down 56.34% YoY) and the FY2025 annual result came in at $9.6 million, down 49.72% from the prior year.
- Non-Current Debt eased to $7.2 million in Q1 2026, from $9.6 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $22.9 million in Q2 2024 to a low of $536000.0 in Q4 2022.
- A 5-year average of $8.1 million and a median of $4.2 million in 2023 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2022 — Non-Current Debt sank 93.78% — and 2024, when it surged 1884.5%.
- Tracing RXRX's Non-Current Debt over 5 years: stood at $536000.0 in 2022, then surged by 105.41% to $1.1 million in 2023, then jumped by 1627.7% to $19.0 million in 2024, then sank by 49.72% to $9.6 million in 2025, then declined by 24.92% to $7.2 million in 2026.
- The last three Non-Current Debt figures came in at $7.2 million (Q1 2026), $9.6 million (Q4 2025), and $11.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | 4.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.75 Mn |
| Mar 31, 2026 | 7.18 Mn |
| Dec 31, 2025 | 9.56 Mn |
| Sep 30, 2025 | 11.90 Mn |
| Jun 30, 2025 | 14.20 Mn |
| Mar 31, 2025 | 16.45 Mn |
| Dec 31, 2024 | 19.02 Mn |
| Sep 30, 2024 | 20.51 Mn |
| Jun 30, 2024 | 22.92 Mn |
| Mar 31, 2024 | 1.07 Mn |
| Dec 31, 2023 | 1.10 Mn |
| Sep 30, 2023 | 1.13 Mn |
| Jun 30, 2023 | 1.16 Mn |
| Mar 31, 2023 | 1.18 Mn |
| Dec 31, 2022 | 536,000.00 |
| Jun 30, 2022 | 586,000.00 |
| Mar 31, 2022 | 610,000.00 |
| Dec 31, 2021 | 633,000.00 |
| Sep 30, 2021 | 3.46 Mn |
| Jun 30, 2021 | 9.42 Mn |